Clinical Trials Global Market Report 2026

Clinical trials are systematically designed research investigations conducted to assess the safety profile, therapeutic effectiveness, appropriate dosage levels, and potential adverse effects of pharmaceutical substances or medical interventions in human subjects. These studies are executed across several sequential phases under tightly regulated conditions to produce robust evidence necessary for regulatory authorization and to support the creation of new medicines and treatment approaches. They adhere to rigorous ethical standards and scientific guidelines to safeguard participant well-being and ensure the accuracy and dependability of the generated data throughout the drug development lifecycle.

The primary service categories in clinical trials include protocol development, site selection or management, data management or biostatistics, and regulatory submission assistance. Protocol development involves creating a detailed and structured study plan that outlines objectives, methodologies, patient eligibility criteria, and trial procedures to ensure both scientific validity and regulatory adherence. Clinical trials are carried out using various study designs such as interventional studies, observational studies, expanded access trials, and other formats, and they are segmented into different phases including Phase I, Phase II, Phase III, Phase IV, and additional phases. These trials are conducted across multiple therapeutic indications such as oncology, cardiovascular conditions, central nervous system disorders, infectious diseases, immunological conditions, and metabolic disorders, and they are utilized by end users including pharmaceutical and biotechnology companies, contract research organizations, as well as academic and research institutions.

Tariffs are affecting the clinical trials market by increasing the expenses associated with imported medical equipment, laboratory consumables, and digital trial management platforms used within global research operations. This leads to delays in trial execution and higher operational costs for pharmaceutical companies, biotechnology firms, and contract research organizations. Among segments, site management or selection and data management or biostatistics are most impacted due to their reliance on international services and technological systems. From a regional perspective, Asia Pacific and Europe experience greater disruption due to their dependence on global outsourcing in clinical research. However, tariffs also support the localization of clinical research infrastructure, strengthen domestic CRO capabilities, and encourage investment in region-specific trial ecosystems, enhancing long-term resilience and self-sufficiency.

The clinical trials market research report is one of a series of new reports from The Business Research Company that provides clinical trials market statistics, including clinical trials industry global market size, regional shares, competitors with a clinical trials market share, detailed clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the clinical trials industry. This clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical trials market size has grown strongly in recent years. It will grow from $127.16 billion in 2025 to $135.51 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to growth of pharmaceutical r&d investment, expansion of global drug development pipelines, increasing prevalence of chronic diseases, establishment of regulatory clinical trial frameworks, rising outsourcing to contract research organizations.

The clinical trials market size is expected to see strong growth in the next few years. It will grow to $176.32 billion by 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to adoption of AI enabled clinical trial design, expansion of precision medicine based trials, growth of decentralized and virtual trials, increasing regulatory emphasis on real world evidence, rising demand for faster drug approval timelines. Major trends in the forecast period include increasing adoption of decentralized clinical trials enabled by digital platforms, rising use of ai driven patient recruitment and trial optimization, growth of real time remote patient monitoring in clinical studies, expansion of patient centric trial designs improving retention rates, increasing outsourcing of clinical trial functions to cros.

The increasing demand for new drug development is anticipated to drive the expansion of the clinical trials market in the forecast period. New drug development refers to the process of discovering, assessing, and introducing new pharmaceutical compounds into the market to address unmet medical needs. The rise in new drug development is fueled by the growing requirement for innovative therapies to treat chronic and complex diseases, resulting in increased research and testing activities. Clinical trials support the demand for new drug development by enabling systematic evaluation of drug safety, efficacy, and regulatory compliance across different trial phases. For instance, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry in Europe, total pharmaceutical production in Europe accounted for €390,000 million ($422,803 million) in 2023, up from €363,300 million ($393,857 million) in 2022. Therefore, the increasing demand for new drug development is driving the expansion of the clinical trials market.

Leading companies operating in the clinical trials market are focusing on developing advanced solutions, such as integrated decentralized clinical trial (DCT) platforms, to improve patient accessibility, streamline trial operations, and enhance data collection efficiency. Decentralized clinical trial platforms refer to technology-driven systems that enable remote patient participation, virtual monitoring, and digital data capture, reducing the need for physical site visits and improving trial flexibility. For example, in June 2024, IQVIA, a US-based provider of advanced analytics, technology solutions, and clinical research services, launched One Home for Sites, a unified clinical trial technology platform designed to support decentralized and hybrid trials. The platform integrates various digital capabilities, including remote patient monitoring, telehealth, eConsent, and data collection tools, into a single interface, enabling seamless trial management, improving patient engagement, and accelerating clinical research outcomes.

In October 2025, Thermo Fisher Scientific Inc., a US-based life sciences and clinical research company, acquired Clario for up to $9.4 billion. Through this acquisition, Thermo Fisher intends to substantially enhance its clinical trial research and data management capabilities by integrating Clario's advanced endpoint data solutions, thereby strengthening its end-to-end clinical development services and enabling more efficient, data-driven execution of clinical trials across global studies. Clario is a US-based clinical research technology company that provides services related to clinical trials.

Major companies operating in the clinical trials market are ICON plc, WuXi AppTec Co Ltd, Charles River Laboratories International Inc, Fortrea Holdings Inc, CMIC Holdings Co Ltd, EPS Holdings Inc, Medpace Holdings Inc, Pharmaron Beijing Co Ltd, Hangzhou Tigermed Consulting Co Ltd, ClinChoice Inc, Worldwide Clinical Trials Holdings Inc, Lambda Therapeutic Research Ltd, Syngene International Ltd, Altasciences Company Inc, KCR SA, Accutest Research Laboratories India Pvt Ltd, Rho Inc

North America was the largest region in the clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The clinical trials market includes revenues earned by entities by providing services such as patient recruitment and retention services, clinical monitoring services, pharmacovigilance and safety reporting, and medical writing and documentation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Clinical Trials Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The clinical trials market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Service Type: Protocol Development; Site Management Or Selection; Data Management Or Biostatistics; Regulatory Submission Support
• 2) By Study Design: Interventional Trials; Observational Trials; Expanded Access Trials; Other Study Designs
• 3) By Phase: Phase I; Phase II; Phase III; Phase IV; Other Phases
• 4) By Indication Or Therapy Area: Oncology; Cardiovascular Diseases; Central Nervous System Disorders; Infectious Diseases; Immunological Disorders; Metabolic Disorders
• 5) By End User: Pharmaceutical And Biotechnology Companies; Contract Research Organizations; Academic And Research Institutes
• Subsegments:
• 1) By Protocol Development: Study Design And Planning Services; Clinical Trial Protocol Writing Services; Dose Selection And Escalation Planning Services; Endpoint Selection And Validation Services; Risk Assessment And Mitigation Planning Services
• 2) By Site Management Or Selection: Investigator Site Identification Services; Site Feasibility Assessment Services; Site Initiation And Activation Services; Site Monitoring And Management Services; Patient Recruitment And Retention Support Services
• 3) By Data Management Or Biostatistics: Clinical Data Collection And Entry Services; Data Validation And Cleaning Services; Statistical Analysis And Modeling Services; Clinical Trial Data Reporting Services; Database Design And Management Services
• 4) By Regulatory Submission Support: Regulatory Documentation Preparation Services; Clinical Trial Application Submission Services; Ethics Committee Submission And Coordination Services; Regulatory Compliance Monitoring Services; Post Submission Support And Query Management Services
• Companies Mentioned: ICON plc; WuXi AppTec Co Ltd; Charles River Laboratories International Inc; Fortrea Holdings Inc; CMIC Holdings Co Ltd; EPS Holdings Inc; Medpace Holdings Inc; Pharmaron Beijing Co Ltd; Hangzhou Tigermed Consulting Co Ltd; ClinChoice Inc; Worldwide Clinical Trials Holdings Inc; Lambda Therapeutic Research Ltd; Syngene International Ltd; Altasciences Company Inc; KCR SA; Accutest Research Laboratories India Pvt Ltd; Rho Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.